Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
PCSK9-LYTAC
- Development stage
- Unknown
- Lead developer
- University of Chinese Academy of Sciences
- Modality
- Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
01
Overview
PCSK9-LYTAC: sourced facts only. name: "Here, we report the development of a bispecific DNA aptamer-based lysosome-targeting chimera (PCSK9-LYTAC) that promotes extracellular degradation of PCSK9 via IGFIIR-mediated lysosomal trafficking." [PMID:41707385]; target: "Here, we report the development of a bispecific DNA aptamer-based lysosome-targeting chimera (PCSK9-LYTAC) that promotes extracellular degradation of PCSK9 via IGFIIR-mediated lysosomal trafficking." [PMID:41707385]; developer: "School of Chemical Sciences, University of Chinese Academy of Sciences, Beijing 100049, PR China; Central Laboratory, Shanxi Province Cancer Hospital/Shanxi Hospital Affiliated to Cancer Hospital, Chinese Academy of Medical Sciences/Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan 030001, Shanxi, China." [PMID:41707385]; modality: "Here, we report the development of a bispecific DNA aptamer-based lysosome-targeting chimera (PCSK9-LYTAC) that promotes extracellular degradation of PCSK9 via IGFIIR-mediated lysosomal trafficking." [PMID:41707385]; stage: "In HepG2 cells, PCSK9-LYTAC efficiently undergoes lysosomal localization and significantly restores LDL uptake (∼22% recovery), outperforming the corresponding monovalent PCSK9 aptamer." [PMID:41707385]
02
Targets
PCSK9 (Proprotein convertase subtilisin/kexin type 9)
Beyond the preview
Go deeper on PCSK9-LYTAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on PCSK9-LYTAC.